Please check your internet connection and try again.
# Ticagrelor
## Overview
Ticagrelor is an oral P2Y12 platelet inhibitor used to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS) or a history of myocardial infarction. It is a direct-acting, reversible antagonist.
## Primary Indications
* **Acute Coronary Syndrome (ACS):** In combination with aspirin, for the prevention of thrombotic events (e.g., myocardial infarction, stroke).
* **History of Myocardial Infarction (MI):** For patients with a history of MI within the last 2 years to reduce the rate of cardiovascular death, MI, and stroke.
## Adult Dosing
* **ACS:**
* **Loading Dose:** 180 mg orally once.
* **Maintenance Dose:** 90 mg orally twice daily for at least 12 months.
* In patients who are at increased risk of bleeding and are being treated with ticagrelor in combination with aspirin, consider a lower maintenance dose of 60 mg twice daily after the first 12 months.
* **History of MI:**
* **Maintenance Dose:** 60 mg orally twice daily.
* Treatment duration should be individualized but is typically continued for at least 12 months.
## Pediatric Dosing
No established pediatric dosing. Ticagrelor is not recommended for use in pediatric patients.
## Dose Adjustments
* **Renal Impairment:** No dose adjustment is recommended for patients with mild, moderate, or severe renal impairment.
* **Hepatic Impairment:** No dose adjustment is recommended for patients with mild to moderate hepatic impairment. Ticagrelor is not recommended in patients with severe hepatic impairment.
## Contraindications
* Active bleeding.
* History of transient ischemic attack (TIA) or stroke.
* Known hypersensitivity to ticagrelor or any of its excipients.
* Concomitant administration with strong CYP3A4 inhibitors is not recommended.
## Adverse Effects
* **Most Common:** Bleeding (including fatal and intracranial), dyspnea, bradycardia, accidental trauma, contusion.
* **Serious:** Major bleeding, ventricular pauses, hyperkalemia, anaphylaxis.
## Key Drug Interactions
* **CYP3A4 Substrates:** Ticagrelor is a moderate inhibitor of CYP3A4. Concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) may increase ticagrelor exposure.
* **CYP3A4 Inducers:** Concomitant use with strong CYP3A4 inducers (e.g., rifampin, carbamazepine) may decrease ticagrelor exposure.
* **CYP2C19 Substrates:** Ticagrelor is a substrate of CYP2C19. Use with caution with drugs that affect CYP2C19 activity.
* **Other Antithrombotics:** Increased risk of bleeding when used with other antithrombotic agents (e.g., anticoagulants, other antiplatelet agents, NSAIDs).
* **Statins:** Ticagrelor may increase simvastatin and atorvastatin exposure; avoid doses greater than 40 mg for simvastatin and 80 mg for atorvastatin.
* **Digoxin:** Ticagrelor may increase digoxin exposure; monitor digoxin levels.
## Monitoring
* **Bleeding:** Closely monitor for signs and symptoms of bleeding, especially in patients with risk factors.
* **Bradycardia:** ECG monitoring may be considered in patients with risk factors for bradycardia.
* **Renal and Hepatic Function:** Routine monitoring is not typically required but consider in patients with significant impairment or as clinically indicated.
* **Electrolytes:** Monitor potassium levels, especially in patients with risk factors for hyperkalemia.
## Clinical Pearls
* Ticagrelor is a reversible P2Y12 inhibitor, unlike clopidogrel which is irreversible. This may allow for a faster return to normal platelet function if discontinuation is needed.
* The 90 mg twice-daily dose is used in ACS patients. The 60 mg twice-daily dose is used in patients with a history of MI or in ACS patients at high bleeding risk after 12 months.
* Avoid concurrent use of ticagrelor with aspirin doses higher than 100 mg, as higher doses may increase bleeding risk without significant benefit in ACS.
* Discontinuation of ticagrelor increases the risk of thrombotic events. If discontinuation is necessary for planned surgery, consider stopping ticagrelor 5 days prior to the procedure.
***
*Disclaimer: This information is intended for healthcare professionals. Always consult the official prescribing information and relevant guidelines for complete and up-to-date details before making clinical decisions.*
